Patient Characteristics and Outcome: Prognostic Value of the Clinical Variables
| Characteristics . | MD . | Patients . | Outcome . | Univariate Analysis P* . | Multivariate Analysis P† . | ||
|---|---|---|---|---|---|---|---|
| No. of Patients . | % . | No. of Events . | 3-yr EFS . | ||||
| All | 82 | 25 | 66% [54-76%] | ||||
| Age ≥10 yr | — | 38 | 46% | 10 | 69% [51-82%] | .81 | — |
| Male | — | 46 | 56% | 12 | 68% [52-81%] | .36 | — |
| St Jude stage | .006 | .54 | |||||
| Stage I and II | 23 | 28% | 2 | 94% [41-68%] | |||
| Stage III and IV | — | 59 | 72% | 23 | 55% [74-99%] | ||
| Ann Arbor stage | .05 | .37 | |||||
| Stage I and II | 25 | 30% | 4 | 86% [66-95%] | |||
| Stage III and IV | — | 57 | 70% | 21 | 57% [42-70%] | ||
| B symptoms | — | 56 | 68% | 20 | 60% [46-73%] | .16 | .25 |
| Adenomegaly | — | 77 | 94% | NA | |||
| Peripheral | — | 72 | 88% | NA | |||
| Intra-abdominal | — | 32 | 39% | NA | |||
| Mediastinal | — | 32 | 39% | 17 | 39% [23-58%] | .0002 | .01 |
| Extra-nodal disease | — | 49 | 60% | NA | |||
| Any visceral involvement | — | 28 | 34% | 15 | 43% [26-62%] | .0004 | .05 |
| Splenomegaly | — | 17 | 21% | 9 | 40% [19-66%] | .02 | .51 |
| Hepatomegaly | — | 14 | 17% | 8 | 38% [16-66%] | .005 | .51 |
| Lung | — | 11 | 13% | 8 | 18% [4-56%] | .00008 | .09 |
| Pleural effusion | — | 6 | 7% | NA | |||
| Other viscera‡ | — | 3 | 4% | NA | |||
| Skin | — | 27 | 33% | 13 | 44% [25-65%] | .01 | .16 |
| Bone marrow | — | 13 | 16% | 6 | 43% [18-72%] | .10 | .67 |
| Bone | — | 10 | 12% | 2 | 78% [45-94%] | .45 | — |
| Soft tissue | — | 10 | 12% | 3 | 64% [32-87%] | .84 | — |
| CNS | — | 0 | 0% | ||||
| LDH ≥800 UI/L | 10 | 13 | 18% | 7 | 37% [16-65%] | .009 | .05 |
| Characteristics . | MD . | Patients . | Outcome . | Univariate Analysis P* . | Multivariate Analysis P† . | ||
|---|---|---|---|---|---|---|---|
| No. of Patients . | % . | No. of Events . | 3-yr EFS . | ||||
| All | 82 | 25 | 66% [54-76%] | ||||
| Age ≥10 yr | — | 38 | 46% | 10 | 69% [51-82%] | .81 | — |
| Male | — | 46 | 56% | 12 | 68% [52-81%] | .36 | — |
| St Jude stage | .006 | .54 | |||||
| Stage I and II | 23 | 28% | 2 | 94% [41-68%] | |||
| Stage III and IV | — | 59 | 72% | 23 | 55% [74-99%] | ||
| Ann Arbor stage | .05 | .37 | |||||
| Stage I and II | 25 | 30% | 4 | 86% [66-95%] | |||
| Stage III and IV | — | 57 | 70% | 21 | 57% [42-70%] | ||
| B symptoms | — | 56 | 68% | 20 | 60% [46-73%] | .16 | .25 |
| Adenomegaly | — | 77 | 94% | NA | |||
| Peripheral | — | 72 | 88% | NA | |||
| Intra-abdominal | — | 32 | 39% | NA | |||
| Mediastinal | — | 32 | 39% | 17 | 39% [23-58%] | .0002 | .01 |
| Extra-nodal disease | — | 49 | 60% | NA | |||
| Any visceral involvement | — | 28 | 34% | 15 | 43% [26-62%] | .0004 | .05 |
| Splenomegaly | — | 17 | 21% | 9 | 40% [19-66%] | .02 | .51 |
| Hepatomegaly | — | 14 | 17% | 8 | 38% [16-66%] | .005 | .51 |
| Lung | — | 11 | 13% | 8 | 18% [4-56%] | .00008 | .09 |
| Pleural effusion | — | 6 | 7% | NA | |||
| Other viscera‡ | — | 3 | 4% | NA | |||
| Skin | — | 27 | 33% | 13 | 44% [25-65%] | .01 | .16 |
| Bone marrow | — | 13 | 16% | 6 | 43% [18-72%] | .10 | .67 |
| Bone | — | 10 | 12% | 2 | 78% [45-94%] | .45 | — |
| Soft tissue | — | 10 | 12% | 3 | 64% [32-87%] | .84 | — |
| CNS | — | 0 | 0% | ||||
| LDH ≥800 UI/L | 10 | 13 | 18% | 7 | 37% [16-65%] | .009 | .05 |
Under patients, the number of patients in the subsets is given. Under outcome, the number of events in the subsets is given. For the variables defining two subgroups, only the data concerning the group with the poorer outcome have been given. The number of events in the complementary group can be deducted by subtraction.
Abbreviations: MD, number of missing data for the variable; NA, not assessed.
P value of the two-tailed logrank test comparing each subset with the complementary group, adjusted on the chemotherapy protocol (univariate analysis).
P value in the multivariate analysis, adjusted on the chemotherapy regimen. The underlined results are those of the variables selected in the final Cox model (P to remove from the model); the other ones are those of the variables rejected from the model (P to enter in the model).
Other viscera are pancreas, kidney, and pericardium.